GE HealthCare Q1 2026: Revenue Beats but EPS Misses as Guidance Cut on Tariffs and Recall

Transcript intelligence

What changed

The most material shift from Q4 2025 to Q1 2026 was the guidance cut. In Q4, management had confidently maintained FY2026 guidance of 3-4% organic growth, EPS of $4.95-$5.15, and $1.7B in free cash flow. By Q1, guidance sentiment moved to lowered as a PDx supplier recall, $250M in inflationary cost impacts (memory chips, freight, oil, metals), and tariff exposure drove adjusted EBIT margin down to 13.5%. Management also completed the Intelerad acquisition, reorganized into three segments (Advanced Imaging Solutions, Pharmaceutical Diagnostics, Patient Care Solutions), and deferred commercial revenue contributions from Photonova Spectra CT and the new 3T MRI platform to 2027. The bullish score declined from 78 to 65 and management tone shifted from confident to cautious.

Guidance delta

Lowered. Full-year EPS guidance was cut from the initial $4.95-$5.15 range established in Q4 2025. A $250 million inflation impact on EPS was flagged, driven by memory chip, freight, oil, and metal cost increases. Adjusted EBIT margin guidance was also reduced, reflecting the PDx supplier quality recall and tariff exposure. Organic revenue growth of 3-4% was maintained, but the profit trajectory deteriorated materially. New product revenue contributions from Photonova Spectra CT and 3T MRI were pushed to 2027.

Key takeaways

• Q1 revenue of $5.1B grew 2.9% organically, beating the $5.04B consensus estimate by 1.8%
• EPS of $0.99 missed the $1.04 estimate by 4.8%, as adjusted EBIT margin slipped to 13.5%
• Full-year EPS and EBIT guidance lowered, citing a PDx supplier recall, $250M inflation impact, and tariff costs
• Intelerad acquisition completed, creating a cloud-first enterprise imaging ecosystem with AI and SaaS capabilities
• Segment reorganization into Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions to sharpen execution and margin
• Photonova Spectra CT and 3T MRI commercial revenue contributions deferred to 2027

Management priorities

• Integrate Intelerad cloud and AI platform across the enterprise imaging ecosystem
• Advance Photonova Spectra photon-counting CT and 3T reduced-helium MRI platform toward 2027 commercial launch
• Develop manganese-based gadolinium-free MRI contrast agent with FDA Fast Track designation, targeting Phase II/III studies and 2029 launch
• Expand AI-embedded and SaaS imaging solutions across modalities to drive recurring services revenue
• Grow pharmaceutical diagnostics and radiopharmaceutical demand, including Flyrcado